Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.

ABSTRACT:

Purpose

Vincristine combined with camptothecin derivatives showed synergy in preclinical pediatric cancer models, and the combinations are effective in treatment of childhood solid tumors. We determined whether the synergy between vincristine and irinotecan extends to eribulin, another microtubule inhibitor.

Experimental design

Vincristine or eribulin, alone or combined with irinotecan, was studied in 12 xenograft models. Tumor regression and time to event were used to assess antitumor activity. Pharmacodynamic studies and RNA sequencing (RNA-seq) were conducted 24 and 144 hours after single-agent or combination treatment. Effects on vascular development were studied in Matrigel plugs implanted in mice. The interaction between binary combinations was examined in vitro

SUBMITTER: Robles AJ 

PROVIDER: S-EPMC7299830 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature